Song Xue

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Acute Myeloid Leukemia

Community Dwelling

Tyrosine Kinase

Stem Cell Transplantation

Top Venues

International journal of laboratory hematology

Leukemia & lymphoma

Cancer innovation

This page only lists publications with an associated author ORCID identifier.

Publications

Li Lin, Song Xue, Jiaqi Chen, Cuihong Gu, Jingzheng Zhang, Enhong Xing, Wei Wang, Lihong Wang, Zhihua Zhang
Olaparib combined with low-dose chemotherapy for relapsed AML1::ETO positive acute myeloid leukemia in elderly patient. Leukemia & lymphoma 65 (8) (2024)
Li Lin, Song Xue, Jiaqi Chen, Cuihong Gu, Jingzheng Zhang, Enhong Xing, Wei Wang, Lihong Wang, Zhihua Zhang
Olaparib combined with low-dose chemotherapy for relapsed AML1::ETO positive acute myeloid leukemia in elderly patient. Leukemia & lymphoma 65 (8) (2024)
Song Xue, Wenqiu Huang, Yongping Zhang, Fuhong Liu, Qi Hao, Jiajun Hu, Lei Yuan, Jingbo Wang
FLT-3 mutation maybe an inferior predictor of daratumumab therapy in acute myeloid leukemia patients relapsed after allogeneic stem cell transplantation. International journal of laboratory hematology (2024)
Song Xue, Wenqiu Huang, Yongping Zhang, Fuhong Liu, Qi Hao, Jiajun Hu, Lei Yuan, Jingbo Wang
FLT-3 mutation maybe an inferior predictor of daratumumab therapy in acute myeloid leukemia patients relapsed after allogeneic stem cell transplantation. International journal of laboratory hematology 46 (4) (2024)
Song Xue, Wenqiu Huang, Yongping Zhang, Fuhong Liu, Qi Hao, Jiajun Hu, Lei Yuan, Jingbo Wang
FLT-3 mutation maybe an inferior predictor of daratumumab therapy in acute myeloid leukemia patients relapsed after allogeneic stem cell transplantation. International journal of laboratory hematology 46 (4) (2024)
Song Xue, Lili Miao, Zimu Gong, Wenqiu Huang, Yongping Zhang, Fuhong Liu, Jingbo Wang
Severe graft-versus-host disease post allogeneic hematopoietic stem cell transplantation due to loss of HLA heterozygosity in recipient lymphocytes after full graft rejection. Cancer innovation 2 (4) (2023)